Private company

PhaseBio Pharmaceuticals Inc

American pharmaceutical preparations company based in Malvern2

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases. Our lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. We are currently conducting our pivotal Phase 3 REVERSE-IT trial of bentracimab.”49

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersMalvern, United States2
  • Incorporated inDE3
  • Business address1 Great Valley Parkway, Suite 30, Malvern, Pa 193553
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300FC27CEJIY52K952
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O INCORPORATING SERVICES, LTD., 19901 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 34789492

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-991.2%Operating margin4
-1210.1%Net margin4
3284.7%Revenue growth, 20214
-$50.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development98¢$102.1M
  • Interest1¢$947.0K
  • Income tax2¢$1.6M

Out of $10.8M in revenue.4 The company lost money this year.

Financial statements

Revenue564$10.8M in 2021+1521% since 2018
0$5.0M$10.0M$15.0M2018: $668.0K$668.0K20182019: $2.4M$2.4M2019+253%2020: $320.0K$320.0K2020−86%2021: $10.8M$10.8M2021+3285%
Operating income7564-$107.4M in 2021+1157% since 2017
-$150.0M-$100.0M-$50.0M02017: -$8.5M-$8.5M20172018: -$19.6M-$19.6M2018+130%2019: -$39.7M-$39.7M2019+102%2020: -$84.9M-$84.9M2020+114%2021: -$107.4M-$107.4M2021+27%
Net income7564-$131.1M in 2021+1179% since 2017
-$150.0M-$100.0M-$50.0M02017: -$10.2M-$10.2M20172018: -$23.8M-$23.8M2018+133%2019: -$39.2M-$39.2M2019+65%2020: -$98.6M-$98.6M2020+151%2021: -$131.1M-$131.1M2021+33%
Fiscal year201620172018201920202021
Revenue$668.0K5$2.4M6$320.0K4$10.8M4
Research and development$6.2M7$15.5M5$30.9M6$72.1M4$102.1M4
Operating expenses$118.2M4
Operating income-$8.5M7-$19.6M5-$39.7M6-$84.9M4-$107.4M4
Interest$2.7M7$3.9M5$1.1M6$1.4M4$947.0K4
Income before tax-$129.5M4
Income tax$07$05$06$04$1.6M4
Net income-$10.2M7-$23.8M5-$39.2M6-$98.6M4-$131.1M4
Earnings per share-$3.394-$2.984
Earnings per share (diluted)-$3.394-$2.984
Shares (weighted, basic)43.9M shares4
Shares (weighted, diluted)43.9M shares4

Compare PhaseBio Pharmaceuticals Inc with another company

Corporate structure

PhaseBio Pharmaceuticals Inc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PhaseBio Pharmaceuticals Inc

  • Avidity Partners Management LP Filed SC 13G/A on PhaseBio Pharmaceuticals Inc, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on PhaseBio Pharmaceuticals Inc, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Rock Springs Capital Management LP Filed SC 13G/A on PhaseBio Pharmaceuticals Inc, latest Feb 14, 2023 (2 filings since Feb 15, 2022)
  • Wellington Management Company Filed SC 13G/A on PhaseBio Pharmaceuticals Inc, latest Feb 6, 2023 (3 filings since Nov 10, 2021)
  • NEW ENTERPRISE ASSOCIATES 13 LP Filed SC 13D/A on PhaseBio Pharmaceuticals Inc, latest Nov 4, 2022
  • MAI Capital Management Filed SC 13G/A on PhaseBio Pharmaceuticals Inc, latest Jul 19, 2022
  • Rosalind Advisors, Inc. Filed SC 13G/A on PhaseBio Pharmaceuticals Inc, latest Feb 14, 2022
  • PhaseBio Pharmaceuticals Inc Malvern, Pennsylvania, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PhaseBio Pharmaceuticals Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.2M4 Dec 31, 2021$10.3M4 Dec 31, 2020+36.7%
Accumulated depreciation$3.9M4 Dec 31, 2021$2.1M4 Dec 31, 2020+84.4%
Property and equipment, net$10.2M4 Dec 31, 2021$8.2M4 Dec 31, 2020+24.4%
Operating-lease assets (leased space)$1.5M4 Dec 31, 2021$1.9M4 Dec 31, 2020−23.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$41.8M4 Dec 31, 2021$28.1M4 Dec 31, 2020+48.6%

Leadership

Who has led PhaseBio Pharmaceuticals Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jonathan P. Mow2018–2022

Chief financial officer

  1. John P. Sharp2018–2022
20202025
Board members and other officers (15)

Former names

  • Phase Biosciences IncSep 18, 2006 to Apr 23, 20083
  • DT BIOSCIENCES INCFeb 25, 2002 to May 11, 20043

Timeline

  1. Aug 15, 20248-K Other events26
  2. Jul 12, 20248-K Bankruptcy or receivership; Other events27
  3. May 16, 20248-K Other events28
  4. Mar 12, 20248-K Entered a material agreement; Other events29
  5. Nov 29, 20238-K Other events30
  6. Oct 3, 20238-K Executive or director change31
  7. Sep 27, 20238-K Other events32
  8. Aug 25, 20238-K Other events33
  9. Jun 30, 20238-K Other events34
  10. May 30, 20238-K Other events35
  11. May 10, 20238-K Other events36
  12. Mar 24, 20238-K Other events37
  13. Oct 17, 2018New chief executive Jonathan P. Mow becomes CEO10
  14. Jan 10, 2002Founded PhaseBio Pharmaceuticals Inc is founded2

Calendar

When it reported results

  1. Aug 12, 2022Reported quarterly or annual results38
  2. May 16, 2022Reported quarterly or annual results39
  3. Mar 24, 2022Reported quarterly or annual results40
  4. Nov 10, 2021Reported quarterly or annual results41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

108 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 34 major events, 40 insider forms, 12 large holders, 18 other. The latest 20:

  1. Sep 30, 202415-12G EDGAR
  2. Sep 30, 2024S-8 POS EDGAR
  3. Sep 30, 2024S-8 POS EDGAR
  4. Sep 30, 2024S-8 POS EDGAR
  5. Sep 30, 2024S-8 POS EDGAR
  6. Sep 30, 2024S-8 POS EDGAR
  7. Aug 15, 2024NT 10-Q EDGAR
  8. Aug 15, 20248-K EDGAR
  9. Jul 12, 20248-K EDGAR
  10. May 16, 2024NT 10-Q EDGAR
  11. May 16, 20248-K EDGAR
  12. Apr 2, 2024NT 10-K EDGAR
  13. Mar 12, 20248-K EDGAR
  14. Nov 29, 20238-K EDGAR
  15. Nov 15, 2023NT 10-Q EDGAR
  16. Oct 3, 20238-K EDGAR
  17. Sep 27, 20238-K EDGAR
  18. Aug 25, 20238-K EDGAR
  19. Aug 25, 2023NT 10-Q EDGAR
  20. Jun 30, 20238-K EDGAR

The 108 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 0 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 25, 2022NEW ENTERPRISE ASSOCIATES 13 LP10% ownerSale1,784,109$0.15$267.6KForm 4
May 23, 2022Burkhardt GlenSVP of Human ResourcesSale11,248$0.79$8.9KForm 4
Nov 19, 2021Burkhardt GlenSVP of Human ResourcesSale5,766$2.37$13.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How PhaseBio Pharmaceuticals Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPhaseBio Pharmaceuticals Inc1
  • CIK0001169245
  • Employer ID (EIN)03-03756971
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1 Great Valley Parkway, Suite 30, Malvern, PA 193551
  • Phone(610) 981-65001
  • Shares outstanding49,858,116 as of Aug 8, 20229
  • Public float$168.9M as of Jun 30, 20214
  • On EDGAR sinceFeb 25, 20021
  • Filings371 in all: 4 (136), 8-K (81), 3 (23), SC 13G/A (18), 10-Q (12), CORRESP (9), SC 13G (8), NT 10-Q (6)1
    All 39 form types

    4/A (5), D (5), S-8 (5), S-8 POS (5), UPLOAD (5), 10-K (4), DEF 14A (4), 424B5 (3), D/A (3), EFFECT (3), REGDEX (3), REGDEX/A (3), SC 13D (3), SC 13D/A (3), 424B4 (2), DRS (2), DRS/A (2), DRSLTR (2), NT 10-K (2), S-1 (2), S-1/A (2), 15-12G (1), 25-NSE (1), 3/A (1), 8-A12B (1), CERT (1), CT ORDER (1), FWP (1), POS EX (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 24, 2022
    Quarterly report (10-Q) Aug 12, 2022
    Proxy statement (DEF 14A) Apr 22, 2022
    Latest 8-K (8-K) Aug 15, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49